| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | MGTA | Common Stock | 1,819,579 | 11 Sep 2023 | See footnote | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | Effective as of September 11, 2023 (the "Effective Time"), a wholly-owned subsidiary of Magenta Therapeutics, Inc. ("Magenta"), merged (the "Merger") with and into Dianthus Therapeutics, Inc. ("Dianthus") resulting in, among other things, Dianthus becoming a wholly owned subsidiary of Magenta. At the Effective Time, Magenta effected a name change to "Dianthus Therapeutics, Inc." (hereinafter, the "Issuer"). |
| F2 | Represents the number of shares of common stock of the Issuer received by the Reporting Persons in the Merger in exchange for the shares of Dianthus held by the Reporting Persons prior to the Merger. Each share of Dianthus common stock held at the Effective Time was exchanged for 0.2181 shares of the Issuer's common stock, which gives effect to the reverse stock split of common stock effected by the Issuer and the Merger exchange ratio. |
| F3 | Consists of (i) 58,129 shares of common stock held of record by Fairmount Healthcare Fund LP, (ii) 1,699,304 shares of common stock held of record by Fairmount Healthcare Fund II LP and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP and Fairmount Healthcare Fund II LP and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Exhibit 24 - Power of Attorney Fairmount, Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.